- Home
- Publications
- Publication Search
- Publication Details
Title
Newer antipsychotics and upcoming molecules for schizophrenia
Authors
Keywords
Schizophrenia, New antipsychotics, Iloperidone, Asenapine, Lurasidone, Blonanserin
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 69, Issue 8, Pages 1497-1509
Publisher
Springer Nature
Online
2013-04-01
DOI
10.1007/s00228-013-1498-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake
- (2013) Yu-Guan Wen et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Striatal and Extrastriatal Dopamine D2 Receptor Occupancy by a Novel Antipsychotic, Blonanserin
- (2013) Amane Tateno et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Retracted: Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia
- (2012) Tomomi Tenjin et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Long-term safety and tolerability of lurasidone in schizophrenia
- (2012) Leslie Citrome et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration
- (2012) Patrick Vigneault et al. PHARMACOLOGICAL RESEARCH
- Evaluation of dopamine D2/D3 and serotonin 5-HT2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography
- (2012) Shunsuke Nakazawa et al. PSYCHOPHARMACOLOGY
- Iloperidone: A new drug for the treatment of schizophrenia
- (2011) S. A. Arif et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia
- (2011) Shu-Wei Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Managing Suicide Risk in Patients with Schizophrenia
- (2011) John Kasckow et al. CNS DRUGS
- Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
- (2011) Kenji Hashimoto et al. CURRENT PHARMACEUTICAL DESIGN
- Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials
- (2011) Leslie Citrome et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats
- (2011) Samantha L McLean et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Novartis to shut brain research facility
- (2011) Alison Abbott NATURE
- Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?
- (2011) Bart A. Ellenbroek NEUROPHARMACOLOGY
- Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
- (2011) Joo-Cheol Shim et al. NEUROPSYCHOPHARMACOLOGY
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
- (2011) C. Hiemke et al. PHARMACOPSYCHIATRY
- Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics
- (2011) Leslie Citrome POSTGRADUATE MEDICINE
- Blonanserin in the treatment of delirium
- (2011) Koji Kato et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission
- (2011) Kent Jardemark et al. PSYCHOPHARMACOLOGY
- A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia
- (2011) Mohammad Arbabi et al. PSYCHOPHARMACOLOGY
- Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
- (2011) Nicholas Seneca et al. PSYCHOPHARMACOLOGY
- Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder
- (2011) Steven G. Potkin et al. SCHIZOPHRENIA RESEARCH
- Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone
- (2011) Philip D. Harvey et al. SCHIZOPHRENIA RESEARCH
- Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
- (2011) Cort A. Pedersen et al. SCHIZOPHRENIA RESEARCH
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
- (2011) Daniel C. Javitt et al. SCHIZOPHRENIA RESEARCH
- Role of sublingual asenapine in treatment of schizophrenia
- (2011) Leslie Citrome Neuropsychiatric Disease and Treatment
- Clinical potential of lurasidone in the management of schizophrenia
- (2011) L Samalin et al. Therapeutics and Clinical Risk Management
- Immediate and Sustained Improvements in Working Memory After Selective Stimulation of α7 Nicotinic Acetylcholine Receptors
- (2010) Stacy A. Castner et al. BIOLOGICAL PSYCHIATRY
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
- (2010) Robert W. Buchanan et al. BIOLOGICAL PSYCHIATRY
- Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia
- (2010) Jaewon Yang et al. CLINICAL NEUROPHARMACOLOGY
- Effect of dose timing in relation to food intake on systemic exposure to blonanserin
- (2010) Junji Saruwatari et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Iloperidone for schizophrenia
- (2010) Jeffrey Rado et al. EXPERT OPINION ON PHARMACOTHERAPY
- Evaluation of the clinical efficacy of asenapine in schizophrenia
- (2010) Arpi Minassian et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic
- (2010) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia
- (2010) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist
- (2010) Yukihiro Ohno et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
- (2010) Norbert Müller et al. SCHIZOPHRENIA RESEARCH
- Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
- (2010) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
- (2010) Akihiro Shiina et al. Annals of General Psychiatry
- Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes
- (2009) Simon Sydserff et al. BIOCHEMICAL PHARMACOLOGY
- Asenapine
- (2009) Juliane Weber et al. CNS DRUGS
- The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia
- (2009) Esther Garcia et al. CNS DRUGS
- Blonanserin
- (2009) Emma D. Deeks et al. CNS DRUGS
- Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models
- (2009) Satoru Yoshikawa et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Lurasidone: a new drug in development for schizophrenia
- (2009) Jonathan M Meyer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission
- (2009) Monica M. Marcus et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia
- (2009) Simona Volpi et al. JOURNAL OF CLINICAL PSYCHIATRY
- Lurasidone in the Treatment of Acute Schizophrenia
- (2009) Mitsutaka Nakamura et al. JOURNAL OF CLINICAL PSYCHIATRY
- Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia
- (2009) David de Lucena et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
- (2009) Yechiel Levkovitz et al. JOURNAL OF CLINICAL PSYCHIATRY
- Procognitive and Neuroprotective Activity of a Novel 7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders
- (2009) R. Roncarati et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model
- (2009) Stefania Risso Bradley et al. NEUROPHARMACOLOGY
- Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
- (2009) Michael Davis et al. NEUROPSYCHOPHARMACOLOGY
- Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia
- (2009) Chantal Schlumberger et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
- (2008) Robert Freedman et al. AMERICAN JOURNAL OF PSYCHIATRY
- Exacerbation of Recurrent Depression as a Result of Treatment With Varenicline
- (2008) MICHAEL K. POPKIN AMERICAN JOURNAL OF PSYCHIATRY
- Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia
- (2008) Andrew J. Cutler et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Long-Term Efficacy and Safety of Iloperidone
- (2008) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Safety Profile of Iloperidone
- (2008) Peter J. Weiden et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Efficacy of Iloperidone in the Treatment of Schizophrenia
- (2008) Steven G. Potkin et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- ADX47273 [S-(4-Fluoro-phenyl)- -methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities
- (2008) F. Liu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle
- (2008) T. B. Halene et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
- (2008) M. Shahid et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study
- (2008) C Lavedan et al. MOLECULAR PSYCHIATRY
- Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia
- (2008) S Volpi et al. MOLECULAR PSYCHIATRY
- A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
- (2008) Jeffrey A Lieberman et al. NEUROPSYCHOPHARMACOLOGY
- Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial
- (2008) Christian Lavedan et al. PHARMACOGENOMICS
- Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040
- (2008) Eric Southam et al. PSYCHOPHARMACOLOGY
- Functional neuroimaging in schizophrenia: diagnosis and drug discovery
- (2008) P MCGUIRE et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started